Phaseline

Targets › CD70

CD70 (CD70 antigen): drug programs, companies and trials

29 programs from 21 companies in 39 trials: 29 Phase 1, 9 Phase 2, 1 Phase 3; Oncology, Immunology, Genitourinary; next expected readout Nov 2026.

Expressed at the plasma membrane of B cells, it is the ligand of the CD27 receptor which is specifically expressed at the surface of T cells. The CD70-CD27 signaling pathway mediates antigen-specific T cell activation and expansion which in turn provides immune surveillance of B cells. (UniProt, P32970)

Open in Phaseline: the race on CD70, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Alpine Immune SciencesPovetacicept (ALPN-303)
Dual CD27/CD70 co-stimulation inhibitor
CD27, CD70Phase 3Immunoglobulin A NephropathyJan 2028
RenJi Hospital[18F]F-RESCA-RCCB6
Trop2/HER2-targeted PET imaging agent
CD70, TROP2, TACSTD2, ERBB2Phase 2Urologic Neoplasms; Renal Cancer; Solid Tumor; Breast CancerNov 2026
RenJi Hospital[18F]F-RESCA-R8B4
CD70-targeted immunoPET imaging agent
CD70Phase 2Renal CancerDec 2026
RenJi Hospital[18F]F-RESCA-RD06
CD70-targeted immunoPET imaging agent
CD70Phase 2Renal CancerDec 2026
RenJi Hospital[68Ga]Ga-NOTA-R8B4
CD70-targeted immunoPET imaging agent
CD70, TROP2Phase 2Renal Cancer; Solid TumorDec 2026
OncoVerityCusatuzumab
CD70 antigen inhibitor
CD70Phase 2Leukemia, Myeloid, AcuteJan 2027
Chongqing Precision BiotechCD70 CAR-T cells
anti-CD70 CAR-T cell therapy
CD70Phase 1Ovarian Cancer; Metastatic TumorDec 2026
Chinese PLA General HospitalCD70-targeting CAR-T cells
CD70-targeted CAR-T cell therapy
CD70Phase 1Solid Tumor, Adult; LymphomaDec 2026
Beijing BiotechEB-701/CA9-NK
Dual-target CD70/CAIX CAR-NK cells
CD70, CA9Phase 1Advanced or Metastatic Clear Cell Renal Cell CarcinomaApr 2027
Tianjin Medical University Cancer Institute and HospitalCHT101
anti-CD70 CAR-T cell therapy
CD70Phase 1Relapsed / Refractory Solid Tumor; Peripheral T-cell LymphomaApr 2027
PfizerSEA-CD70
anti-CD70 antibody-drug conjugate
CD70Phase 1Myelodysplastic SyndromeJul 2027
The Children's Hospital of Zhejiang University School of Medicineanti-BCMA/CD70 CAR-T cells
CAR-T cell therapy targeting BCMA and CD70
BCMA, CD70Phase 1Multi-Drug Resistant Nephrotic SyndromeJul 2027
Second Affiliated Hospital, Zhejiang University, School of MedicineCD70 CAR-NK
Anti-CD70 CAR-NK cell therapy
CD70Phase 1Relapsed/Refractory T-cell LymphomaNov 2027
University of Florida8R-70CAR T cells
IL-8 receptor (CXCR2)-modified CD70 CAR T cell therapy
CXCR2, CD70Phase 1Glioblastoma Multiforme; Brain MetastasesDec 2027
Qilu PharmaceuticalQLS2309
anti-CD70 antibody-drug conjugate
CD70Phase 1Relapsed or Refractory Hematologic MalignanciesDec 2027
Aibin Liang,MD,Ph.D.dualCAR-NK19/70 cell
anti-CD19/CD70 CAR-NK cell therapy
CD19, CD70Phase 1Refractory or Relapsed B-cell Non-Hodgkin LymphomaJan 2028
M.D. Anderson Cancer CenterTGFBR-2 KO CD70 CAR NK
Allogeneic TGF-β receptor 2 knockout CD70-targeted CAR NK cell therapy
CD70Phase 1Clear Cell CarcinomaFeb 2028
Allogene TherapeuticsALLO-329
Allogeneic dual CAR T-cell therapy targeting CD19 and CD70
CD19, CD70Phase 1Systemic Lupus Erythematosus (With and Without Nephritis)Feb 2028
The Children's Hospital of Zhejiang University School of Medicineanti-BCMA/CD70-CAR-T cells
CAR-T cells targeting BCMA and CD70
BCMA, CD70Phase 1CAR T Cell TherapyApr 2028
Chongqing Precision BiotechBCMA/CD70 CAR-T cells
Dual-targeted CAR-T cell therapy against BCMA and CD70
TNFRSF17, CD70Phase 1Systemic Lupus ErythematosusAug 2028
Chongqing Precision BiotechBCMA/CD70-targeted CAR-T
Dual-targeted CAR-T cell therapy against BCMA and CD70
BCMA, CD70Phase 1Juvenile Dermatomyositis (JDM)Sep 2028
National Cancer Institute (NCI)Anti-hCD70 CAR transduced PBL
CD70-binding chimeric antigen receptor (CAR) on transduced peripheral blood lymphocytes
CD70Phase 1Pancreatic CancerJan 2029
Hrain BiotechnologyAnti-Human CD70 T-Cell Injection
Anti-CD70 CAR-T cell therapy
CD70Phase 1Renal Cell Carcinoma (RCC)Jun 2029
Baylor College of MedicineCD70.CAR
CD70-targeting chimeric antigen receptor (CAR) T cell therapy
CD70Phase 1Leukemia, Myeloid, AcuteJun 2029
Allogene TherapeuticsALLO-316
Allogeneic CAR T cell therapy targeting CD70
CD70Phase 1Advanced/Metastatic Clear Cell Renal Cell CarcinomaJan 2030
St. Jude Children's Research HospitalCD70-CAR T cell infusion (Autologous)
anti-CD70 CAR-T cell therapy
CD70Phase 1Hematologic MalignancyJul 2030
M.D. Anderson Cancer CenterCAR.70/IL15-transduced CB-NK cells
CAR-T cell therapy targeting CD70 with IL-15 transduction in natural killer cells derived
CD70Phase 1B-Cell LymphomaAug 2030
Adicet TherapeuticsADI-270
anti-CD70 CAR-T cell therapy (engineered gamma-delta Vδ1 T cells)
CD70Phase 1Clear Cell Renal Cell Carcinoma–
Peking University Cancer Hospital & InstituteCGC738
CD70-targeted CAR-NKT cell therapy
CD70Phase 1Advanced Malignant Solid Tumors–

Conditions

Renal Cancer (4) Leukemia, Myeloid, Acute (4) Solid Tumor (2) Relapsed / Refractory Solid Tumor (1) Peripheral T-cell Lymphoma (1) Refractory or Relapsed B-cell Non-Hodgkin Lymphoma (1) Advanced/Metastatic Clear Cell Renal Cell Carcinoma (1) Glioblastoma Multiforme (1) Brain Metastases (1) Myelodysplastic Syndrome (1) Solid Tumor, Adult (1) Lymphoma (1)

Modalities

other (10), small molecule (9), mixed (7), protein or peptide (2), antibody (1)

Companies

RenJi Hospital (4) Chongqing Precision Biotech (3) Allogene Therapeutics (2) M.D. Anderson Cancer Center (2) The Children's Hospital of Zhejiang University School of Medicine (2) Tianjin Medical University Cancer Institute and Hospital (1) Aibin Liang,MD,Ph.D. (1) University of Florida (1) Pfizer (1) Chinese PLA General Hospital (1) Beijing Biotech (1) Alpine Immune Sciences (1) St. Jude Children's Research Hospital (1) Baylor College of Medicine (1) OncoVerity (1) Qilu Pharmaceutical (1) National Cancer Institute (NCI) (1) Peking University Cancer Hospital & Institute (1) Hrain Biotechnology (1) Second Affiliated Hospital, Zhejiang University, School of Medicine (1)

Related targets

BCMA (3) CD19 (2) TROP2 (2) CXCR2 (1) CA9 (1) TACSTD2 (1) ERBB2 (1) CD27 (1) TNFRSF17 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.